Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Chronic lymphocytic leukemia (CLL) exhibits challenges in treatment due to drug resistance and relapse.
• Chronic inflammation and immune dysfunction are key factors in CLL pathogenesis.
• The pro-inflammatory protein S100A9 is implicated in various cancers and autoimmune diseases.

Purpose of the Study:

• To investigate the role of S100A9 in CLL progression.
• To elucidate the molecular mechanisms underlying S100A9's function in CLL.
• To evaluate S100A9 as a potential therapeutic target for CLL.

Main Methods:

• Analysis of exosomes released by CLL patients.
• Utilizing in vivo mouse models (Eµ-TCL1 and Eµ-TCL1/S100A9-/-).
• Employing patient-derived xenograft (PDX) models for pharmacological targeting.

Main Results:

• CLL patients release exosomes containing S100A9, correlating with NF-κB activation.
• A novel S100A9/EMMPRIN interaction mechanism was identified in CLL.
• Pharmacological targeting of S100A9 demonstrated therapeutic potential in preclinical models.

Conclusions:

• S100A9 plays a significant role in CLL progression and immune modulation.
• The S100A9/EMMPRIN axis represents a novel therapeutic target in CLL.
• Targeting S100A9 holds potential for clinical application in CLL treatment.